Neuroprotective astrocyte-derived insulin/insulin-like growth factor 1 stimulates endocytic processing and extracellular release of neuron-bound Aβ oligomers
Open accessThe DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
Abstract
Synaptopathy underlying memory deficits in Alzheimer’s disease (AD) is increasingly thought to be instigated by toxic oligomers of the amyloid beta peptide (AβOs). Given the long latency and incomplete penetrance of AD dementia with respect to Aβ pathology, we hypothesized that factors present in the CNS may physiologically protect neurons from the deleterious impact of AβOs. Here we employed physically separated neuron–astrocyte cocultures to investigate potential non–cell autonomous neuroprotective factors influencing AβO toxicity. Neurons cultivated in the absence of an astrocyte feeder layer showed abundant AβO binding to dendritic processes and associated synapse deterioration. In contrast, neurons in the presence of astrocytes showed markedly reduced AβO binding and synaptopathy. Results identified the protective factors released by astrocytes as insulin and insulin-like growth factor-1 (IGF1). The protective mechanism involved release of newly bound AβOs into the extracellular medium dependent upon trafficking that was sensitive to exosome pathway inhibitors. Delaying insulin treatment led to AβO binding that was no longer releasable. The neuroprotective potential of astrocytes was itself sensitive to chronic AβO exposure, which reduced insulin/IGF1 expression. Our findings support the idea that physiological protection against synaptotoxic AβOs can be mediated by astrocyte-derived insulin/IGF1, but that this protection itself is vulnerable to AβO buildup.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 1×
“Experimentally, AβOs instigate memory failure (Lesne et al., 2006) and AD neuropathology, including tau hyperphosphorylation and synapse dysfunction and deterioration (De Felice et al., 2007, 2008; Lacor et al., 2007; Ma et al., 2009; Balducci et al., 2010; Nimmrich et al., 2010; Tomiyama et al.,…”
BackgroundRetractedThe amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164 · cited 2×
“The major Aβ species implicated in AD pathogenesis comprise soluble AβOs (Mucke and Selkoe, 2012; Selkoe and Hardy, 2016; DiChiara et al., 2017).”
BackgroundJack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Hearing loss and cognitive decline in older adults
Lin, F. R., Yaffe, K., Xia, J., Xue, Q.-L., Harris, T. B., Purchase-Helzner, E., Satterfield, S., Ayonayon, H. N., Ferrucci, L., Simonsick, E. M., et al. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.1868 · Cited by 4,017
The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease
Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · cited 3×
“, 2009), such an accelerating feedback loop would likely require several levels of therapeutic intervention, optimally combining anti-AβO therapy using antibodies capable of recognizing oligomers, such as Aducanumab (Sevigny et al., 2016), together with CNS-targeted insulin therapy (Craft et al.”
BackgroundInfluentialKarran, E., Mercken, M., & Strooper, B. D. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3505 · Cited by 2,188 · cited 1×
“There has been considerable controversy regarding the involvement of Aβ-derived toxins in AD pathogenesis (Karran et al., 2011).”
BackgroundDecreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078 · cited 1×
“AβO levels also can be reduced by clearance from interstitial fluid (Mawuenyega et al., 2010; Takeda et al., 2013).”
BackgroundTalbot, K., Wang, H.-Y., Kazi, H., Han, L.-Y., Bakshi, K. P., Stucky, A., Fuino, R. L., Kawaguchi, K. R., Samoyedny, A. J., Wilson, R. S., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59903 · Cited by 1,871 · cited 2×
“…insulin/IGF1 expression Given the association of impaired insulin/IGF1 signaling with AD dementia (Rivera et al., 2005; Bomfim et al., 2012; Craft et al., 2012; Talbot et al., 2012), we investigated whether insulin/IGF1 expression in neural cells was disrupted by AβOs (500 nM, 8 d) using qRT-PCR.”
BackgroundMethodA mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738 · cited 1×
“This is strongly supported by the discovery of the Icelandic A673T mutation in APP; this mutation decreases Aβ production and protects carriers against AD onset (Jonsson et al., 2012).”
BackgroundCNS synaptogenesis promoted by glia-derived cholesterol
Mauch, D. H., Nägler, K., Schumacher, S., Göritz, C., Müller, E.-C., Otto, A., & Pfrieger, F. W. (2001) · Science · doi:10.1126/science.294.5545.1354 · Cited by 1,711 · cited 2×
“Release of bound AβOs is mediated by insulin/IGF1 Astrocytes constitute the main source of growth factors in the CNS and play major roles in brain morphogenesis, including neuronal survival and maturation, precursor proliferation, and neuronal circuitry formation (Araque et al., 1998; Gomes et al., 1999; Mauch et al.,…”
BackgroundThrombospondins are astrocyte-secreted proteins that promote CNS synaptogenesis
Christopherson, K. S., Ullian, E. M., Stokes, C. C. A., Mullowney, C. E., Hell, J. W., Agah, A., Lawler, J., Mosher, D. F., Bornstein, P., & Barres, B. A. (2005) · Cell · doi:10.1016/j.cell.2004.12.020 · Cited by 1,688 · cited 4×
“Release of bound AβOs is mediated by insulin/IGF1 Astrocytes constitute the main source of growth factors in the CNS and play major roles in brain morphogenesis, including neuronal survival and maturation, precursor proliferation, and neuronal circuitry formation (Araque et al., 1998; Gomes et al., 1999; Mauch et al.,…”
BackgroundInfluentialPrevalence of Cerebral Amyloid Pathology in Persons Without Dementia: A Meta-analysis
Jansen, W. J., Ossenkoppele, R., Knol, D. L., Tijms, B. M., Scheltens, P., Verhey, F. R. J., Visser, P. J., Aalten, P., Aarsland, D., Alcolea, D., et al. (2015) · JAMA · doi:10.1001/jama.2015.4668 · Cited by 1,610
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., & Sabatini, B. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4970-06.2007 · Cited by 1,592 · cited 1×
“Accumulation of AβOs leads to spine deterioration, synapse failure, and, eventually, synapse loss (Lacor et al., 2007; Shankar et al., 2007; Koffie et al., 2009; Wilcox et al., 2011; Sivanesan et al., 2013).”
BackgroundCellular prion protein mediates impairment of synaptic plasticity by amyloid-β oligomers
Laurén, J., Gimbel, D. A., Nygaard, H. B., Gilbert, J. W., & Strittmatter, S. M. (2009) · Nature · doi:10.1038/nature07761 · Cited by 1,560
Long-term potentiation depends on release of d-serine from astrocytes
Henneberger, C., Papouin, T., Oliet, S. H. R., & Rusakov, D. A. (2010) · Nature · doi:10.1038/nature08673 · Cited by 1,389 · cited 1×
“…which includes glutamate (Parpura et al., 1994; Cavelier and Attwell, 2005), adenosine/ATP (Panatier et al., 2011; Schmitt et al., 2012), transforming growth factor beta 1 (Diniz et al., 2012, 2014, 2017), thrombospondin (Christopherson et al., 2005), and dserine (Henneberger et al., 2010).”
BackgroundControl of Synaptic Strength by Glial TNFα
Beattie, E. C., Stellwagen, D., Morishita, W., Bresnahan, J. C., Ha, B. K., Von Zastrow, M., Beattie, M. S., & Malenka, R. C. (2002) · Science · doi:10.1126/science.1067859 · Cited by 1,344
Alzheimer’s disease β-amyloid peptides are released in association with exosomes
Rajendran, L., Honsho, M., Zahn, T. R., Keller, P., Geiger, K. D., Verkade, P., & Simons, K. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603838103 · Cited by 1,343
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · cited 7×
“, 2006) and AD neuropathology, including tau hyperphosphorylation and synapse dysfunction and deterioration (De Felice et al., 2007, 2008; Lacor et al., 2007; Ma et al., 2009; Balducci et al., 2010; Nimmrich et al., 2010; Tomiyama et al., 2010; Sebollela et al., 2012; Figueiredo et al., 2013).”
BackgroundInfluentialSelf-citationPlaque-independent disruption of neural circuits in Alzheimer’s disease mouse models
Hsia, A. Y., Masliah, E., McConlogue, L., Yu, G.-Q., Tatsuno, G., Hu, K., Kholodenko, D., Malenka, R. C., Nicoll, R. A., & Mucke, L. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.6.3228 · Cited by 1,123 · cited 2×
“semblies that begin to accumulate before amyloid plaques (Hsia et al., 1999; Oddo et al., 2006).”
BackgroundApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., et al. (2012) · Science · doi:10.1126/science.1217697 · Cited by 1,050
Neurotoxicity of Amyloid -Protein: Synaptic and Network Dysfunction
Mucke, L., & Selkoe, D. J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006338 · Cited by 1,000 · cited 3×
“The major Aβ species implicated in AD pathogenesis comprise soluble AβOs (Mucke and Selkoe, 2012; Selkoe and Hardy, 2016; DiChiara et al., 2017).”
BackgroundSynaptic Targeting by Alzheimer's-Related Amyloid β Oligomers
Lacor, P. N., Buniel, M. C., Chang, L., Fernandez, S. J., Gong, Y., Viola, K. L., Lambert, M. P., Velasco, P. T., Bigio, E. H., Finch, C. E., et al. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3432-04.2004 · Cited by 954 · cited 1×
“…disrupt synaptic cytoskeletal proteins and receptor trafficking, and ultimately lead to synapse loss (Lambert et al., 1998; Walsh et al., 2002; Lacor et al., 2004, 2007; Monitoring Editor Robert G. Parton University of Queensland Received: Jun 21, 2017 Accepted: Jul 31, 2017 This article was…”
BackgroundSelf-citationDe Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · cited 1×
“…instigate memory failure (Lesne et al., 2006) and AD neuropathology, including tau hyperphosphorylation and synapse dysfunction and deterioration (De Felice et al., 2007, 2008; Lacor et al., 2007; Ma et al., 2009; Balducci et al., 2010; Nimmrich et al., 2010; Tomiyama et al., 2010; Sebollela et…”
BackgroundSelf-citationApoE Promotes the Proteolytic Degradation of Aβ
Jiang, Q., Lee, C. Y. D., Mandrekar, S., Wilkinson, B., Cramer, P., Zelcer, N., Mann, K., Lamb, B., Willson, T. M., Collins, J. L., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.04.010 · Cited by 876 · cited 1×
“First, buildup of AβOs is slowed by Aβ degradation (Jiang et al., 2008; Cramer et al., 2012), which can be mediated by astrocytes and microglia (Mandrekar-Colucci et al.”
BackgroundKoffie, R. M., Meyer-Luehmann, M., Hashimoto, T., Adams, K. W., Mielke, M. L., Garcia-Alloza, M., Micheva, K. D., Smith, S. J., Kim, M. L., Lee, V. M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811698106 · Cited by 850 · cited 4×
“appearance, attributable to association with dendritic arbors (Kayed et al., 2003; Lacor et al., 2007; Koffie et al., 2009).”
BackgroundMethodInfluentialRegulation of synaptic connectivity by glia.
Eroglu, C., & Barres, B. A. (2010) · Nature · doi:10.1038/nature09612 · Cited by 813 · cited 1×
“We focused on astrocytes because of their well-established trophic functions (Chernausek, 1993; Grunblatt et al., 2007; Eroglu and Barres, 2010; Diniz et al., 2014).”
BackgroundInsulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation
Qiu, W. Q., Walsh, D. M., Ye, Z., Vekrellis, K., Zhang, J., Podlisny, M. B., Rosner, M. R., Safavi, A., Hersh, L. B., & Selkoe, D. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32730 · Cited by 812
Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors
Allen, N. J., Bennett, M. L., Foo, L. C., Wang, G. X., Chakraborty, C., Smith, S. J., & Barres, B. A. (2012) · Nature · doi:10.1038/nature11059 · Cited by 764 · cited 2×
“Release of bound AβOs is mediated by insulin/IGF1 Astrocytes constitute the main source of growth factors in the CNS and play major roles in brain morphogenesis, including neuronal survival and maturation, precursor proliferation, and neuronal circuitry formation (Araque et al., 1998; Gomes et al., 1999; Mauch et al.,…”
BackgroundMoloney, A. M., Griffin, R. J., Timmons, S., O’Connor, R., Ravid, R., & O’Neill, C. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2008.04.002 · Cited by 764 · cited 1×
“This decrease is consistent with findings that insulin and IGF1 expression in the CNS is reduced in AD patients (Rivera et al., 2005; Gil-Bea et al., 2010; Moloney et al., 2010).”
ResultRivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., & de la Monte, S. M. (2005) · Journal of Alzheimer s Disease · doi:10.3233/jad-2005-8304 · Cited by 723 · cited 2×
“…cells chronically exposed to AβOs show reduced insulin/IGF1 expression Given the association of impaired insulin/IGF1 signaling with AD dementia (Rivera et al., 2005; Bomfim et al., 2012; Craft et al., 2012; Talbot et al., 2012), we investigated whether insulin/IGF1 expression in neural cells…”
BackgroundResultEarly-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease
Jacobsen, J. S., Wu, C.-C., Redwine, J. M., Comery, T. A., Arias, R., Bowlby, M., Martone, R., Morrison, J. H., Pangalos, M. N., Reinhart, P. H., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0600948103 · Cited by 701
Zempel, H., Thies, E., Mandelkow, E., & Mandelkow, E.-M. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2357-10.2010 · Cited by 686 · cited 2×
“In the absence of astrocytes, neurons exposed to AβOs exhibited 0.33 ± 0.03 spinophilin puncta per micrometer, a 44% decrease compared with control neurons Koffie et al., 2009; Tomiyama et al., 2010; Zempel et al., 2010; Figueiredo et al., 2013).”
BackgroundMethodInfluentialDe Felice, F. G., Vieira, M. N. N., Bomfim, T. R., Decker, H., Velasco, P. T., Lambert, M. P., Viola, K. L., Zhao, W.-Q., Ferreira, S. T., & Klein, W. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0809158106 · Cited by 657 · cited 6×
“These findings confirm and extend previous indications that insulin signaling protects neurons against AβOs and AD pathogenesis (Townsend et al., 2007; Jolivalt et al., 2008; De Felice et al., 2009; Zhao et al., 2009; Craft et al., 2012; Long-Smith et al., 2013).”
BackgroundResultInfluentialSelf-citationAstrocytes Are Endogenous Regulators of Basal Transmission at Central Synapses
Panatier, A., Vallée, J., Haber, M., Murai, K. K., Lacaille, J.-C., & Robitaille, R. (2011) · Cell · doi:10.1016/j.cell.2011.07.022 · Cited by 650
Amyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · cited 8×
“…insulin signaling further by reducing insulin/IGF-1 expression (as found here) or by instigating removal of insulin receptors and inhibition of IRS-1 (Zhao et al., 2008; Bomfim et al., 2012); and 4) the resulting major dysfunction in insulin/IGF1 signaling allows oligomer binding to reach toxic…”
BackgroundInfluentialSuppression of glymphatic fluid transport in a mouse model of Alzheimer's disease
Peng, W., Achariyar, T. M., Li, B., Liao, Y., Mestre, H., Hitomi, E., Regan, S., Kasper, T., Peng, S., Ding, F., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2016.05.015 · Cited by 580 · cited 2×
“Regulation of Aβ levels by glia (Koenigsknecht and Landreth, 2004; Yin et al., 2006) and its clearance by the glymphatic system (Peng et al., 2016) represent likely protective mechanisms.”
BackgroundMa, Q.-L., Yang, F., Rosario, E. R., Ubeda, O. J., Beech, W., Gant, D. J., Chen, P. P., Hudspeth, B., Chen, C., Zhao, Y., et al. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.1071-09.2009 · Cited by 536 · cited 3×
“, 2006) and AD neuropathology, including tau hyperphosphorylation and synapse dysfunction and deterioration (De Felice et al., 2007, 2008; Lacor et al., 2007; Ma et al., 2009; Balducci et al., 2010; Nimmrich et al., 2010; Tomiyama et al., 2010; Sebollela et al., 2012; Figueiredo et al., 2013).”
BackgroundDinkins, M. B., Dasgupta, S., Wang, G., Zhu, G., & Bieberich, E. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.012 · Cited by 494 · cited 1×
“It has been suggested that exosomes may be involved in the molecular mechanisms of AD (Rajendran et al., 2006; Yuyama et al., 2012; Dinkins et al., 2014).”
BackgroundDeleterious Effects of Amyloid β Oligomers Acting as an Extracellular Scaffold for mGluR5
Renner, M., Lacor, P. N., Velasco, P. T., Xu, J., Contractor, A., Klein, W. L., & Triller, A. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.029 · Cited by 468 · cited 4×
“Inhibition of insulin signaling leads to irreversible AβO binding Because AβOs progressively self-associate to form large extracellular complexes on the neuronal surface (Renner et al., 2010), we tested whether delaying insulin stimulation could make bound oligomers resistant to release induced by insulin.”
BackgroundResultInfluentialSelf-citationSynthetic amyloid-β oligomers impair long-term memory independently of cellular prion protein
Balducci, C., Beeg, M., Stravalaci, M., Bastone, A., Sclip, A., Biasini, E., Tapella, L., Colombo, L., Manzoni, C., Borsello, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911829107 · Cited by 466 · cited 1×
“…al., 2006) and AD neuropathology, including tau hyperphosphorylation and synapse dysfunction and deterioration (De Felice et al., 2007, 2008; Lacor et al., 2007; Ma et al., 2009; Balducci et al., 2010; Nimmrich et al., 2010; Tomiyama et al., 2010; Sebollela et al., 2012; Figueiredo et al., 2013).”
BackgroundThe Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442 · cited 3×
“The relationship between AβOs and CNS insulin signaling overall is surprisingly complex (Ferreira and Klein, 2011; De Felice, 2013).”
BackgroundSelf-citationAlzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432
Self-citationZafra, F., Lindholm, D., Castren, E., Hartikka, J., & Thoenen, H. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-12-04793.1992 · Cited by 414
Tomiyama, T., Matsuyama, S., Iso, H., Umeda, T., Takuma, H., Ohnishi, K., Ishibashi, K., Teraoka, R., Sakama, N., Yamashita, T., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.5825-09.2010 · Cited by 396 · cited 4×
“, 2006) and AD neuropathology, including tau hyperphosphorylation and synapse dysfunction and deterioration (De Felice et al., 2007, 2008; Lacor et al., 2007; Ma et al., 2009; Balducci et al., 2010; Nimmrich et al., 2010; Tomiyama et al., 2010; Sebollela et al., 2012; Figueiredo et al., 2013).”
BackgroundMethodInfluentialSelf-citationMatrix Metalloproteinases Expressed by Astrocytes Mediate Extracellular Amyloid-β Peptide Catabolism
Yin, K.-J., Cirrito, J. R., Yan, P., Hu, X., Xiao, Q., Pan, X., Bateman, R., Song, H., Hsu, F.-F., Turk, J., et al. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.2085-06.2006 · Cited by 381
Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease
Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379 · cited 2×
“In AD patients and mouse models, AβOs accumulate early, before plaque buildup (Jacobsen et al., 2006; Oddo et al., 2006; Lacor et al., 2007) and possibly decades before clinical symptoms develop (Jack et al., 2010).”
BackgroundSelf-citationMandrekar-Colucci, S., Karlo, J. C., & Landreth, G. E. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5268-11.2012 · Cited by 355 · cited 1×
“, 2012), which can be mediated by astrocytes and microglia (Mandrekar-Colucci et al., 2012), and stimulated by peroxisome proliferator-activated receptor-γ, a known insulin-sensitizing factor.”
BackgroundSoluble Aβ Inhibits Specific Signal Transduction Cascades Common to the Insulin Receptor Pathway
Townsend, M., Mehta, T., & Selkoe, D. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610390200 · Cited by 318 · cited 1×
“These findings confirm and extend previous indications that insulin signaling protects neurons against AβOs and AD pathogenesis (Townsend et al., 2007; Jolivalt et al., 2008; De Felice et al., 2009; Zhao et al., 2009; Craft et al., 2012; Long-Smith et al., 2013).”
ResultMonoclonal antibodies that target pathological assemblies of Aβ
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314 · cited 1×
“Anti-AβO antibodies NU1 (1.5 μg/ml) and NU4 (1.5 μg/ml) are monoclonal antibodies derived from mice immunized with AβOs (Lambert et al., 2007).”
BackgroundInfluentialSelf-citationUsenovic, M., Niroomand, S., Drolet, R. E., Yao, L., Gaspar, R. C., Hatcher, N. G., Schachter, J., Renger, J. J., & Parmentier-Batteur, S. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.1523-15.2015 · Cited by 245 · cited 1×
“Of note, recent microfluidics experiments strongly indicate that cellular transmission of ADtype tau can be propagated by exosomes (Usenovic et al., 2015).”
BackgroundAmyloid accelerates tau propagation and toxicity in a model of early Alzheimer’s disease
Pooler, A. M., Polydoro, M., Maury, E. A., Nicholls, S. B., Reddy, S. M., Wegmann, S., William, C., Saqran, L., Cagsal-Getkin, O., Pitstick, R., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0199-x · Cited by 236
Zhao, W.-Q., Santini, F., Breese, R., Ross, D., Zhang, X. D., Stone, D. J., Ferrer, M., Townsend, M., Wolfe, A. L., Seager, M. A., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.057182 · Cited by 188 · cited 1×
“The ability of insulin to stimulate endocytosis in neurons is well known, including the endocytosis of potential AβO-binding proteins (Zhao et al., 2010).”
BackgroundKnowles, J. K., Rajadas, J., Nguyen, T.-V. V., Yang, T., LeMieux, M. C., Vander Griend, L., Ishikawa, C., Massa, S. M., Wyss-Coray, T., & Longo, F. M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.0620-09.2009 · Cited by 184 · cited 1×
“Proteinaceous Aβ binding sites, including APP (Shaked et al., 2006; Fogel et al., 2014) and p75NTR (Knowles et al., 2009), are known to undergo proteolytic cleavage that could lead to the release of surface-bound AβOs (Sotthibundhu et al., 2008; Kenchappa et al., 2010).”
BackgroundPereira Diniz, L., Tortelli, V., Matias, I., Morgado, J., Bérgamo Araujo, A. P., Melo, H. M., Seixas da Silva, G. S., Alves-Leon, S. V., de Souza, J. M., Ferreira, S. T., et al. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.3351-16.2017 · Cited by 171 · cited 1×
“It has been suggested that exosomes may be involved in the molecular mechanisms of AD (Rajendran et al., 2006; Yuyama et al., 2012; Dinkins et al., 2014).”
BackgroundSelf-citationInsulin Receptor Dysfunction Impairs Cellular Clearance of Neurotoxic Oligomeric Aβ
Zhao, W.-Q., Lacor, P. N., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.011015 · Cited by 154
Self-citationFogel, H., Frere, S., Segev, O., Bharill, S., Shapira, I., Gazit, N., O’Malley, T., Slomowitz, E., Berdichevsky, Y., Walsh, D. M., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.04.024 · Cited by 138 · cited 1×
“Proteinaceous Aβ binding sites, including APP (Shaked et al., 2006; Fogel et al., 2014) and p75NTR (Knowles et al., 2009), are known to undergo proteolytic cleavage that could lead to the release of surface-bound AβOs (Sotthibundhu et al., 2008; Kenchappa et al., 2010).”
BackgroundPitt, J., Roth, W., Lacor, P., Smith, A. B., Blankenship, M., Velasco, P., De Felice, F., Breslin, P., & Klein, W. L. (2009) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2009.07.018 · Cited by 134 · cited 3×
“AβOs and FAM-AβOs were prepared as previously described (Pitt et al., 2009).”
MethodInfluentialShaked, G. M., Kummer, M. P., Lu, D. C., Galvan, V., Bredesen, D. E., Koo, E. H., Shaked, G. M., Kummer, M. P., Lu, D. C., Galvan, V., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-5032fje · Cited by 132
Cited by
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
Self-citationCraft, S., Raman, R., Chow, T. W., Rafii, M. S., Sun, C.-K., Rissman, R. A., Donohue, M. C., Brewer, J. B., Jenkins, C., Harless, K., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.1840 · Cited by 389
Brain Insulin Resistance and Hippocampal Plasticity: Mechanisms and Biomarkers of Cognitive Decline
Spinelli, M., Fusco, S., & Grassi, C. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00788 · Cited by 280
Michinaga, S., & Koyama, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030571 · Cited by 263
Amyloid-β oligomers in cellular models of Alzheimer’s disease
Fontana, I. C., Zimmer, A. R., Rocha, A. S., Gosmann, G., Souza, D. O., Lourenco, M. V., Ferreira, S. T., & Zimmer, E. R. (2020) · Journal of Neurochemistry · doi:10.1111/jnc.15030 · Cited by 115
“…(Zhao et al., 2009) • ApoE3 and ApoE4 influence on Aβ-uptake (Lin et al., 2018); • TGF-β1 ↑ neuroprotection (Diniz et al., 2017); • Insulin and IGF-1 ↑ neuroprotection (Pitt et al., 2017); • mGluR5 clustering (Shrivastava et al., 2013); • ↑ ATP levels (Shrivastava et al., 2013); • ER stress…”
Self-citation
Metadata
- Authors
- Pitt, J., Wilcox, K. C., Tortelli, V., Diniz, L. P., Oliveira, M. S., Dobbins, C., Yu, X.-W., Nandamuri, S., Gomes, F. C. A., DiNunno, N., Viola, K. L., De Felice, F. G., Ferreira, S. T., & Klein, W. L.
- Venue
- Molecular Biology of the Cell
- Published
- 2017-10
- Volume
- 28
- Issue
- 20
- Pages
- 2623-2636
- ISSN
- 1059-1524 (ISSN-L)
- 1939-4586
- OpenAlex
- W2744662591
- Cited by
- 84
- References
- 58
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.